Argatroban promotes recovery of spinal cord injury by inhibiting the PAR1/JAK2/STAT3 signaling pathway

• Published in: Neural regeneration research 2024-02, Vol.19 (2), p.434-439
• Main Authors: Zhao, Chenxi, Zhou, Tiangang, Li, Ming, Liu, Jie, Zhao, Xiaoqing, Pang, Yilin, Liu, Xinjie, Zhang, Jiawei, Ma, Lei, Li, Wenxiang, Yao, Xue, Feng, Shiqing
• Format: Article
• Language: English
• Subjects: Anticoagulants; argatroban; astrogliosis; jak/stat signaling pathway; protease-activated receptor-1; spinal cord injury; thrombin; vimentin; Spinal cord injuries
• ISSN: 1673-5374; 1876-7958
• DOI: 10.4103/1673-5374.375345

Argatroban is a synthetic thrombin inhibitor approved by U.S. Food and Drug Administration for the treatment of thrombosis. However, whether it plays a role in the repair of spinal cord injury is unknown. In this study, we established a rat model of T10 moderate spinal cord injury using an NYU Impactor Moder III and performed intraperitoneal injection of argatroban for 3 consecutive days. Our results showed that argatroban effectively promoted neurological function recovery after spinal cord injury and decreased thrombin expression and activity in the local injured spinal cord. RNA sequencing transcriptomic analysis revealed that the differentially expressed genes in the argatroban-treated group were enriched in the JAK2/STAT3 pathway, which is involved in astrogliosis and glial scar formation. Western blotting and immunofluorescence results showed that argatroban downregulated the expression of the thrombin receptor PAR1 in the injured spinal cord and the JAK2/STAT3 signal pathway. Argatroban also inhibited the activation and proliferation of astrocytes and reduced glial scar formation in the spinal cord. Taken together, these findings suggest that argatroban may inhibit astrogliosis by inhibiting the thrombin-mediated PAR1/JAK2/STAT3 signal pathway, thereby promoting the recovery of neurological function after spinal cord injury.